|
|
Marketing Authorisations
|
|
|
|
|
For selected patients, with cardiac monitoring
|
|
|
|
|
|
|
|
|
|
|
|
After chemotherapy: better than docetaxel
|
|
|
|
|
|
|
|
|
|
Risk of infection outweights any benefit
|
|
|
|
|
|
|
|
|
|
The risks of an immunosuppressant, but no efficacy
|
|
|
|
|
|
|
|
|
|
Reviews
|
|
|
|
|
First-choice treatments
|
|
|
|
|
|
|
|
|
|
In heart failure with atrial fibrillation
|
|
|
|
|
|
|
|
|
|
|
|